Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to explore the potential benefit of the medication, pentoxifylline, for the treatment of NASH.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Treatments: Pentoxifylline

Criteria

Inclusion Criteria:

1. Subjects must be willing to give written informed consent

2. Diagnosis of steatohepatitis Grade >= 1 (Brunt et al. criteria - Am J Gastroenterology 1999;94(9)2467-74) on biopsy within 6 months prior to entry into protocol

3. No histologic evidence of cirrhosis

4. Persistent ALT elevation (> 1.5 the upper limit normal) over 6 months prior to entry into study

5. Adult subjects 18-65 years of age of any race or gender

6. Compensated liver disease with the following hematologic, biochemical, and serological criteria on entry into protocol:

• Hemoglobin > 11 gm/dL for females and > 12 gm/dL for males

• White blood cell (WBC) > 2.5 K/UL

• Neutrophil count > 1.5 K/UL

• Platelets > 100 K/UL

• Direct bilirubin, within normal limits

• Indirect bilirubin within normal limits (unless non-hepatitis factors such as Gilbert's disease explain indirect bilirubin rise. In such cases total bilirubin must be < 3.0 mg/dL)

• Albumin > 3.2 g/dL

• Serum creatinine within normal limits

7. Hemoglobin A1c (HgbA1c) < 7%

8. Antinuclear antibodies (ANA) < 1:160

9. Anti-smooth muscle Ab negative

10. Serum hepatitis B surface antigen (HepBsAg) negative

11. Serum hepatitis C antibody (HepC Ab) negative

12. Iron/total iron binding capacity (TIBC) ratio (transferrin saturation) < 45%

13. Alpha-1-antitrypsin level within normal limits

14. Ceruloplasmin level within normal limits

15. Negative pregnancy test (females)

16. Concomitant use of lipid lowering agents at study entry will not exclude patients from the study.

Exclusion Criteria:

1. Evidence of decompensated cirrhosis

2. Active gastrointestinal (GI) bleeding

3. Renal failure (creatinine clearance < 80 mL/min)

4. Active alcohol or drug abuse

5. Uncontrolled diabetes (HgbA1c > 7)

6. Current treatment with anti-diabetic medications such as thiazolidinediones or metformin (stable doses of sulfonylureas are acceptable)

7. Current treatment with anti-TNF alpha medication (i.e. Remicade or Enbrel)

8. Current treatment with vitamin E

9. Alcohol consumption < 20 g/day (males) or < 10 g/day (females) - assessed by one physician and confirmed with one family member.

10. HIV positive status

11. Any history of cerebral and/or retinal hemorrhage

12. Prior intolerance of pentoxifylline or any other methylxanthine (i.e. caffeine, theophylline, or theobromine)

13. Current use of theophylline

14. Known diagnosis of malignancy

15. Any other conditions which the investigator feels would make the subject unsuitable for enrollment, or could interfere with the subject completing the protocol